GlassScriptPhysician profile
William T Weiss
NPI 1386713808
$2,497.58
in general payments reported to CMS, 2019-2025
26 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $209 · 2021: $546 · 2022: $236 · 2023: $325 · 2024: $380 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $452.26 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $419.62 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $317.19 | 2019-2023 | Belsomra |
| Lilly USA, LLC | $193.73 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $117.81 | 2021-2023 | Dalvance |
| Astrazeneca Pharmaceuticals LP | $104.68 | 2019-2025 | Breztri |
| Sumitomo Pharma America, INC. | $93.14 | 2024-2025 | Gemtesa |
| C2n Diagnostics, LLC | $90.18 | 2025 | Precivityad2 |
| Eisai INC. | $85.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.49 | 2025 | |
| Amarin Pharma, INC. | $56.30 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $46.37 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.35 | 2019-2020 | |
| Allergan, INC. | $45.04 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.64 | 2022-2023 | Livalo |
| Azurity Pharmaceuticals, INC. | $36.36 | 2023 | Edarbi |
| Pfizer INC. | $33.22 | 2019-2023 | |
| Glaxosmithkline, LLC. | $29.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.82 | 2024 | Spravato |
| Stryker Corporation | $24.44 | 2023 | Variax |
| Xeris Pharmaceuticals, INC. | $20.15 | 2023 | Keveyis |
| Sunovion Pharmaceuticals INC. | $18.51 | 2022 | |
| Nevro Corp. | $16.93 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.26 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.